The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD).
The hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.
Patient aged 18 or over
Men and women
Patients affiliated with a social-security organization
Patients undergoing a myelo-ablative allo-HSCT for a controlled haematologic malignant disease, with peripheral stem cells, whatever the type of donor (except cord blood)
Status of tumor progression at the time of allo-HSCT
Inability to understand the protocol (linguistic barrier, cognitive difficulties)
Medical history of another progressive cancer or occurrence in the 3 previous years (excluding basal cell carcinoma)
Presence of a simultaneous serious and uncontrolled disease (severe cardiac, renal, hepatic or respiratory failure, severe sepsis)
University Hospital, Clermont-Ferrand
Lead sponsor
Ministry of Health, France
Collaborator
French Society of Hematology
Collaborator